BioMarin Pharmaceutical Inc. has filed for European approval of its investigational drug for a rare, genetic disorder that causes progressive muscle wasting. The company said that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for drisapersen, an investigational antisense oligonucleotide drug candidate for the …
Tag Archives: BioMarin Pharmaceuticals
June, 2015
March, 2015
-
19 March
Myriad Expands Collaboration with BioMarin for Cancer Companion Diagnostic Test
Myriad Genetics recently announced that it has expanded its collaboration with BioMarin Pharmaceutical to use Myriad’s myChoice HRD companion diagnostic test. Under the deal, BioMarin will use Myriad’s myChoice HRD companion diagnostic test to prospectively identify patients with metastatic breast, ovarian and potentially other tumor types that may be sensitive …